SUDA welcomes Australian Government’s Initiatives to Foster Medical Marijuana Industry

To increase the bioavailability of administered medications, Australian-headquartered SUDA Pharmaceuticals Ltd (ASX: SUD) is reformulating medications into an oral spray. The delivery of medications...
SUDA Pharmaceuticals: Pharmacy And Pharmacology Journal Publishes Impressive ZolpiMistTM Clinical Study Results

SUDA Pharmaceuticals: Pharmacy And Pharmacology Journal Publishes Impressive ZolpiMistTM Clinical Study Results

SUDA Pharmaceuticals Ltd (ASX: SUD) is an oro-mucosal drug delivery company that is reformulating medication into an oral spray to improve the bioavailability of...

SUDA’s June Quarterly Report Out On ASX; A Look At Its Business And Technology

On 31 July 2019, SUDA Pharmaceuticals Ltd (ASX: SUD), an oro-mucosal drug delivery firm, has released its June quarterly updates on the ASX. SUDA...

SUDA’s MD and CEO, Mr Stephen Carter Back on Board

An oro-mucosal drug delivery company headquartered in Perth, SUDA Pharmaceuticals Ltd (ASX: SUD) uses its OroMist® technology for the development of low-risk oral sprays....

SUDA Receives Patent For The Only Effective Medicine For Platelet Reduction, Anagrelide; Stock Soars...

With the rise in cases of the deadly disease cancer creating havoc across the globe, it is the need of the hour for the...

Latest News

Editorial